Sublingual five-grass pollen tablets (Oralair®): A guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis

被引:0
|
作者
Lyseng-Williamson K.A. [1 ]
机构
[1] Adis, Mairangi Bay, North Shore 0754, Auckland
关键词
Allergic Rhinitis; Pollen Season; Grass Pollen; World Allergy Organization; Allergen Immunotherapy;
D O I
10.1007/s40267-014-0131-7
中图分类号
学科分类号
摘要
Sublingual 300 IR five-grass pollen allergen extract tablets (Oralair®) are a valuable option in patients with grass-pollen induced allergic rhinoconjunctivitis. Allergen immunotherapy with sublingual five-grass pollen tablets beginning 4 months before and continuing throughout the grass pollen season reduces the symptoms of allergic rhinoconjunctivitis and the use of symptomatic rescue medications during the pollen season. Precautions should be followed to minimize the risk of systemic and local allergic reactions that may occur with allergen immunotherapy. © 2014 Springer International Publishing.
引用
收藏
页码:200 / 208
页数:8
相关论文
共 50 条
  • [21] Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis
    Wahn, Ulrich
    Tabar, Ana
    Kuna, Piotr
    Halken, Susanne
    Montagut, Armelle
    de Beaumont, Olivier
    Le Gall, Martine
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (01) : 160 - 166
  • [22] The effect of specific immunotherapy (SIT) on grass pollen-induced rhinoconjunctivitis
    Arsovski, Z
    Dokic, D
    Gavrilovski, M
    Kaeva, B
    Goseva, Z
    ALLERGY, 2002, 57 : 54 - 54
  • [23] Economic evaluation of five-grass pollen tablets for the treatment of allergic rhinitis
    Ruggeri, M.
    Oradei, M.
    Frati, F.
    Puccinelli, P.
    Romao, C.
    Cicchetti, A.
    ALLERGY, 2012, 67 : 419 - 419
  • [24] Treatment Satisfaction During Sublingual Immunotherapy with a Five-Grass Pollen Tablet for Allergic Rhinoconjunctivitis: A Prospective, Non-Interventional Study
    Schäfer U.
    Kienle-Gogolok A.
    Hadler M.
    Karagiannis E.
    Schnitzer S.
    Drugs - Real World Outcomes, 2017, 4 (2) : 109 - 117
  • [25] An evaluation of data on the relative clinical impact of sublingual allergen immunotherapy tablets and symptomatic medications in grass-pollen-induced allergic rhinoconjunctivitis
    Devillier, P.
    Dreyfus, J-F
    Demoly, P.
    Didier, A.
    de Beaumont, O.
    Calderon, M.
    ALLERGY, 2013, 68 : 71 - 71
  • [26] A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis
    Philippe Devillier
    Jean-François Dreyfus
    Pascal Demoly
    Moisés A Calderón
    BMC Medicine, 12
  • [27] A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis
    Devillier, Philippe
    Dreyfus, Jean-Francois
    Demoly, Pascal
    Calderon, Moises A.
    BMC MEDICINE, 2014, 12
  • [28] Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis
    Dahl, Ronald
    Kapp, Alexander
    Colombo, Giselda
    deMonchy, Jan G. R.
    Rak, Sabina
    Emminger, Waltraud
    Rivas, Montserrat Fernandez
    Ribel, Mette
    Durham, Stephen R.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (02) : 434 - 440
  • [29] An assessment of sustained efficacy and safety of a 300IR five-grass pollen sublingual immunotherapy tablet in adults with grass pollen induced allergic rhinoconjunctivitis during a 3-year treatment study
    Didier, A.
    Horak, F.
    Worm, M.
    Melac, M.
    de Beaumont, O.
    Le Gall, M.
    Montagut, A.
    Galvain, S.
    Malling, H.
    ALLERGY, 2010, 65 : 172 - 172
  • [30] Immunological biomakers of grass allergen tablets in grass pollen rhinoconjunctivitis patients
    Didier, A.
    Montagut, A.
    Fadef, R.
    Melac, M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S124 - S124